Mylan Inc., of Pittsburgh, said its subsidiary in India, Mylan Laboratories Ltd., a manufacturer of antiretroviral (ARV) drugs, has been selected, through its South African-based subsidiary Mylan Ltd., as one of the leading suppliers of ARV medications to the South African National Department of Health for the period April 1, 2015, to March 31, 2018. Read More
Nephrogenex Inc., of Raleigh, N.C., completed a QT/QTc cardiac safety study on Pyridorin. This study assesses a drug's risk of QT prolongation and its proarrhythmic potential, and is a standard component of all clinical development programs for new molecular entities. Read More
Sucampo Pharmaceuticals Inc., of Bethesda, Md., said Health Canada has accepted its new drug submission for Amitiza (lubiprostone), 24 mcg capsules, for the treatment of chronic idiopathic constipation in adults and opioid induced constipation in adults with chronic non-cancer pain. Read More
BioWorld's offices were closed on Thursday, Jan. 1, in observance of the New Year's Day holiday in the U.S. No issues were published that day. Read More
Cristal Therapeutics BV raised €6 million (US$7.5 million) in a series A round, enough to take the company through a first clinical trial involving its Cripec nanotechnology platform. Read More
Researchers have used a novel screening method to gain insight into the causes behind both intrinsic and acquired resistance that can foil treatment with targeted cancer therapies. Read More
The confirmation of Merck & Co. Inc.'s impending acquisition of Cubist Pharmaceuticals Inc. in early December 2014 has provided Merck with access to the market for developing novel antibiotics and combating superbugs. The deal is the latest indication that major pharmaceutical companies could be focusing their attention back to antibiotic development following decades of low investment. Read More
Philadelphia-based Spark Therapeutics Inc. put an exclamation point on a year that has seen gene therapy capture the attention of biotech investors big time by filing a S-1 registration statement for its proposed initial public offering (IPO) of its common stock. Read More
